Clozapine Versus “High-Dose” Olanzapine in Refractory Early-Onset Schizophrenia: An Open-Label Extension Study
Authors:
- 1 August 2008
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 18 (4) , 307-316
Abstract
Objective: A recent 12-week controlled comparison demonstrated the superiority of clozapine to “high-dose” olanzapine in adolescents with treatment-refractory schizophrenia. In the present study, the authors conducted a 12-week, open-label, follow-up study to examine changes in lipid and glucose metabolism in youths maintained on clozapine and to determine whether patients who were previously randomized to high-dose olanzapine (up to 30 mg/day) responded to clozapine. Method: Thirty three (14 clozapine, 19 olanzapine) (85%) of 39 patients were available for the present 12-week, open-label extension study. Extended safety data using an intention-to-treat analysis from the 14 subjects treated with clozapine for a total of 24 weeks are presented. In addition, we report the clinical outcomes for 10 of 19 olanzapine-treated patients who were switched after 12 weeks to clozapine due to treatment nonresponse. Clinical response was defined as a decrease of 30% or more in total Brief Psychiatric Rating score from week 12 and a Clinical Global Impression–Improvement rating of 1 (very much improved) or 2 (much improved). Results: The incidence of hypertriglyceridemia (defined as fasting triglycerides >125 mg/dL) (10/14 = 71%) and the incidence of “prediabetes” (defined as fasting blood glucose ≥100) (4/14 = 29%) at week 24 in the clozapine-treated subjects were notable. Seven (70%) of 10 of young patients with schizophrenia who failed treatment with “high-dose” olanzapine were found to respond to a 12-week, open-label clozapine trial. Conclusions: Clinicians and caregivers need to be aware of potential metabolic adverse events of long-term clozapine treatment. Adolescents with a poor response to olanzapine may do better on clozapine.Keywords
This publication has 33 references indexed in Scilit:
- Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophrenia Research, 2007
- ReplyActa Psychiatrica Scandinavica, 2006
- The Choice of Antipsychotic Drugs for SchizophreniaNew England Journal of Medicine, 2005
- Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and MortalityThe Journal of Clinical Psychiatry, 2005
- An exploratory open‐label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophreniaActa Psychiatrica Scandinavica, 2005
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2004
- A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week TrialNeuropsychopharmacology, 2003
- Hyperglycemia from Olanzapine Treatment in AdolescentsJournal of Child and Adolescent Psychopharmacology, 2003
- Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With OlanzapineAmerican Journal of Psychiatry, 2002
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970